Yahoo Web Search

Search results

1. • 

     BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial

     Clinical Trials Arena via Yahoo Finance· 3 days ago

     Bristol Myers Squibb’s (BMS) blockbuster cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab)...

2. • 

     Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

     Zacks via Yahoo Finance· 2 days ago

     Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails...

3. • 

     Bristol Myers Squibb reports setback in lung cancer trial By Investing.com

     Investing.com· 5 days ago

     The study evaluated the efficacy of Opdivo in combination with chemoradiotherapy, and subsequent...

4. • 

     Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint

     The Wall Street Journal· 5 days ago

     HEALTH NEWS Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer...

5. • 

     2 Beaten-Down Stocks to Buy and Hold for 10 Years

     Motley Fool via Yahoo Finance· 6 days ago

     However, the drugmaker isn't out of the woods just yet. Cancer drug Opdivo is one of the company's top-selling products, but it will run out of patent...

6. • 

     Is Bristol Myers' Dividend in Danger?

     Motley Fool via Yahoo Finance· 5 days ago

     Rising costs and minimal growth pose a problem for Bristol Myers as many of the drugmaker's top drugs, including Eliquis, Revlimid, and Opdivo, are...

7. • 

     Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in...

     FOX 4 Kansas City· 6 days ago

     The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety,...

8. • 

     Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs

     BenefitsPRO· 6 days ago

     Bristol-Myers Squibb has announced that it plans to cut $1.5 billion in expenses by the end of 2025,...

9. • Aethlon Medical Stock Surges In Pre-market On Positive Hemopurifier Trial Results

     RTT News· 6 days ago

     In pre-market activity on the Nasdaq, Aethlon shares were surging more than 101 percent to trade at $2.44. The company noted that the translational study provides pre-clinical evidence to support ...

10. • 

      Down but Not Out: 3 Stocks to Buy on a Post-Earnings Dip

      Motley Fool via Yahoo Finance· 4 days ago

      As if that earnings miss weren't enough, the company faces a patent cliff, with Eliquis and Opdivo...